Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.

BACKGROUND Although second primary cancers are a leading cause of death among men with testicular cancer, few studies have quantified risks among long-term survivors. METHODS Within 14 population-based tumor registries in Europe and North America (1943-2001), we identified 40,576 1-year survivors of testicular cancer and ascertained data on any new incident solid tumors among these patients. We used Poisson regression analysis to model relative risks (RRs) and excess absolute risks (EARs) of second solid cancers. All statistical tests were two-sided. RESULTS A total of 2,285 second solid cancers were reported in the cohort. The relative risk and EAR decreased with increasing age at testicular cancer diagnosis (P < .001); the EAR increased with attained age (P < .001) but the excess RR decreased. Among 10-year survivors diagnosed with testicular cancer at age 35 years, the risk of developing a second solid tumor was increased (RR = 1.9, 95% confidence interval [CI] = 1.8 to 2.1). Risk remained statistically significantly elevated for 35 years (RR = 1.7, 95% CI = 1.5 to 2.0; P < .001). We observed statistically significantly elevated risks, for the first time, for cancers of the pleura (malignant mesothelioma; RR = 3.4, 95% CI = 1.7 to 5.9) and esophagus (RR = 1.7, 95% CI = 1.0 to 2.6). Cancers of the lung (RR = 1.5, 95% CI = 1.2 to 1.7), colon (RR = 2.0, 95% CI = 1.7 to 2.5), bladder (RR = 2.7, 95% CI = 2.2 to 3.1), pancreas (RR = 3.6, 95% CI = 2.8 to 4.6), and stomach (RR = 4.0, 95% CI = 3.2 to 4.8) accounted for almost 60% of the total excess. Overall patterns were similar for seminoma and nonseminoma patients, with lower risks observed for nonseminoma patients treated after 1975. Statistically significantly increased risks of solid cancers were observed among patients treated with radiotherapy alone (RR = 2.0, 95% CI = 1.9 to 2.2), chemotherapy alone (RR = 1.8, 95% CI = 1.3 to 2.5), and both (RR = 2.9, 95% CI = 1.9 to 4.2). For patients diagnosed with seminomas or nonseminomatous tumors at age 35 years, cumulative risks of solid cancer 40 years later (i.e., to age 75 years) were 36% and 31%, respectively, compared with 23% for the general population. CONCLUSIONS Testicular cancer survivors are at statistically significantly increased risk of solid tumors for at least 35 years after treatment. Young patients may experience high levels of risk as they reach older ages. The statistically significantly increased risk of malignant mesothelioma in testicular cancer survivors has, to our knowledge, not been observed previously in a cohort of patients treated with radiotherapy.

[1]  Erik Holmberg,et al.  Radiation Effects on Breast Cancer Risk: A Pooled Analysis of Eight Cohorts , 2002, Radiation research.

[2]  B. Schmitz-Dräger,et al.  Lifestyle issues and genitourinary tumours , 2004, World Journal of Urology.

[3]  H. Schultz,et al.  [Cancer of the testis]. , 1980, Ugeskrift for laeger.

[4]  C. Catton,et al.  Management of stage II seminoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Tarone,et al.  Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. , 1993, Environmental health perspectives.

[6]  F. Liddell,et al.  Simple exact analysis of the standardised mortality ratio. , 1984, Journal of epidemiology and community health.

[7]  S. Fosså,et al.  Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Neugut,et al.  Incidence of malignant pleural mesothelioma after thoracic radiotherapy , 1997, Cancer.

[9]  C. Bokemeyer,et al.  Treatment of testicular cancer and the development of secondary malignancies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Pierce,et al.  Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. , 1995, Journal of the National Cancer Institute.

[11]  R. Motzer,et al.  Testicular germ-cell cancer. , 1997, The New England journal of medicine.

[12]  R. Weichselbaum,et al.  Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Tong.  Long-term medical care of testicular cancer survivors. , 2003, Annals of internal medicine.

[14]  P Fraser,et al.  Radiation dose and second cancer risk in patients treated for cancer of the cervix. , 1988, Radiation research.

[15]  A. Stiggelbout,et al.  Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Preston,et al.  Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. , 2002, Journal of the National Cancer Institute.

[17]  R. Kleinerman,et al.  Second cancer following cancer of the male genital system in Connecticut, 1935-82. , 1985, National Cancer Institute monograph.

[18]  B. Levin,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[19]  G. Hanks,et al.  Seminoma of the testis: long-term beneficial and deleterious results of radiation. , 1992, International journal of radiation oncology, biology, physics.

[20]  D. Preston,et al.  Cancer incidence in atomic bomb survivors. Part I: Use of the tumor registries in Hiroshima and Nagasaki for incidence studies. , 1994, Radiation research.

[21]  J. Lubin,et al.  Cancer following radiotherapy for peptic ulcer. , 1994, Journal of the National Cancer Institute.

[22]  B. Hankey,et al.  Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience. , 1984, Journal of the National Cancer Institute.

[23]  M. Stovall,et al.  Tissue doses from radiotherapy of cancer of the uterine cervix. , 1989, Medical physics.

[24]  R. Lothe,et al.  Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. , 1990, British Journal of Cancer.

[25]  R N Hoover,et al.  Second cancer following cancer of the female genital system in Connecticut, 1935-82. , 1985, National Cancer Institute monograph.

[26]  P. Hall,et al.  Treatment-associated leukemia following testicular cancer. , 2000, Journal of the National Cancer Institute.

[27]  K. Hemminki,et al.  Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. , 2001, European journal of cancer.

[28]  S. Fosså,et al.  A randomised trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18) - Preliminary report , 2002 .

[29]  C. Muirhead,et al.  Variations with time and age in the risks of solid cancer incidence after radiation exposure in childhood. , 1998, Statistics in medicine.

[30]  A. Hagenbeek,et al.  Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. , 1995, Journal of the National Cancer Institute.

[31]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2004 , 2004, CA: a cancer journal for clinicians.

[32]  Arthur Gerl, Rudolf Schierl.  Urinary Excretion of Platinum in Chemotherapy-treated Long-term Survivors of Testicular Cancer , 2000, Acta oncologica.

[33]  M. Stovall,et al.  Lung cancer risk and radiation dose among women treated for breast cancer. , 1994, Journal of the National Cancer Institute.

[34]  A. Neugut,et al.  Radiation Therapy for Breast Cancer and Increased Risk for Esophageal Carcinoma , 1998, Annals of Internal Medicine.

[35]  A. Brahme,et al.  Principles and Practice of Radiation Oncology , 1992 .

[36]  S. Tretli,et al.  Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. , 1997, European journal of cancer.

[37]  E. Viacava,et al.  [Testicular tumors]. , 1950, Boletines y trabajos de la Academia Argentina de Cirugia. Academia Argentina de Cirugia.

[38]  H. Storm,et al.  Incidence of second primary cancer following testicular cancer. , 1993, European journal of cancer.

[39]  MD B. J. Kennedy,et al.  National survey of patterns of care for testis cancer , 1987, Cancer.

[40]  L. G. Lewis.  Testis tumors. , 1949, Advances in surgery.

[41]  A. Barrett,et al.  ORCHIDECTOMY ALONE IN TESTICULAR STAGE I NON-SEMINOMATOUS GERM-CELL TUMOURS , 1982, The Lancet.

[42]  J. Horton,et al.  CLINICAL ONCOLOGY , 1978, The Ulster Medical Journal.

[43]  J. Fraumeni,et al.  Lung Cancer after Treatment for Hodgkin's Disease: Focus on Radiation Effects , 2003, Radiation research.

[44]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[45]  P. Sparén,et al.  Second primary cancer after treatment for cervical cancer. An international cancer registries study , 1995, Cancer.

[46]  C. Land,et al.  Malignant Neoplasms after Radiation Therapy for Peptic Ulcer , 2002, Radiation research.

[47]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.

[48]  J. Maier,et al.  Carcinoma of the testis , 1977, Cancer.

[49]  P. Hall,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[50]  F. Berthier,et al.  Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  D. Preston,et al.  Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. , 1994, Radiation research.

[52]  K. Weiss,et al.  Definition and estimation of lifetime detriment from radiation exposures: principles and methods. , 1992, Health physics.

[53]  A. Horwich,et al.  Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Steven A. Leibel,et al.  Textbook of Radiation Oncology , 1998 .

[55]  S. Seal,et al.  Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours , 2000, Nature Genetics.

[56]  S. Fosså,et al.  Increased mortality rates in young and middle-aged patients with malignant germ cell tumours , 2004, British Journal of Cancer.

[57]  S. Fosså,et al.  Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  L. Einhorn.  Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. , 1981, Cancer research.

[59]  G. Steele,et al.  Cancer: Principles and Practice of Oncology , 1983 .

[60]  M. Coleman,et al.  EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  C. Bokemeyer,et al.  Secondary neoplasms following treatment of malignant germ cell tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[63]  D. Sleijfer,et al.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.

[64]  U. Rüther,et al.  Second Malignancies following Pure Seminoma , 2000, Oncology.

[65]  C. Metayer,et al.  “Second Malignant Neoplasms Among Long-Term Survivors of Hodgkinʼs Disease: A Population-Based Evaluation Over 25 Years” , 2002 .

[66]  岩崎 民子.  SOURCES AND EFFECTS OF IONIZING RADIATION : United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR 2000 Report to the General Assembly, with Scientific Annexes , 2002 .

[67]  A. Horwich,et al.  Mortality and cancer incidence following radiotherapy for seminoma of the testis. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[68]  D. Raghavan.  Principles and practice of genitourinary oncology , 1997 .

[69]  W. Travis,et al.  Post‐irradiation malignant mesothelioma , 1996, Cancer.

[70]  V. Devita,et al.  The use of drugs in combination for the treatment of cancer: rationale and results. , 1973, The New England journal of medicine.

[71]  L. Travis.  Therapy-associated Solid Tumors , 2002, Acta oncologica.

[72]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[73]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[74]  Andrew K. Lee,et al.  Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Charles Mw,et al.  Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. , 2003 .

[76]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.